Cerevance reports Solengepras reduced daily OFF time in Parkinson’s study
Cerevance announced positive topline results from ARISE, its randomized, double-blind, placebo-controlled Phase 3 trial of once-daily oral Solengepras as an adjunctive treatment for people with Parkinson’s disease experiencing motor fluctuations. Solengepras 150 mg met the trial’s primary endp
<p>Cerevance announced positive topline results from ARISE, its randomized, double-blind, placebo-controlled Phase 3 trial of once-daily oral Solengepras as an adjunctive treatment for people with Parkinson’s disease experiencing motor fluctuations. Solengepras 150 mg met the trial’s primary endp</p>